Incidence of COVID-19 in a cohort of dermatology patients receiving immunomodulating biologic medications

Int J Dermatol. 2021 Dec;60(12):e500-e501. doi: 10.1111/ijd.15922. Epub 2021 Sep 30.

Authors

Mahin Alamgir¹, Marielle Jamgochian¹, Jennifer Cucalon², Shazli Razi³, Banu Farabi⁴, Babar Rao^{1

3}

Affiliations

¹ Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA.
² St George's University School of Medicine, Grenada, Dominica.
³ Rao Dermatology, New York, NY, USA.
⁴ Department of Internal Medicine, St Peter's University Hospital, New Brunswick, NJ, USA.

No abstract available

Publication types

Letter

MeSH terms

Biological Products* / adverse effects
COVID-19*
Dermatology*
Humans
Incidence
SARS-CoV-2

Substances

Biological Products